Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.